UKUK

100% premium: Novartis buys antibiotics specialists Neutec Pharma

21.07.2006

London – Another UK biotech company was taken over when Novartis signed a recommended all-cash offer worth Euro435 million for the antibiotics specialists Neutec pharma. The Swiss pharma giant paid more than twice of the Manchester-based company’s market capitalization before the takeover approach. Buying Neutec gives Novartis access to two advanced stage antibody products for serious hospital-acquired infections: Mycograb, for treating systemic fungal infections and Aurograb, for treating methicillin-resistant Staphylococcus aureus. Daniel Vasella, CEO of Novartis, said the products “promise to dramatically improve treatments in the area and will also enable Novartis to strengthen its biologics pipeline and anti-infective drug portfolio.” Mycograb has been filed in Europe and has been approved for compassionate use, while Aurograb is in phase III. NeuTec has retained 100% ownership of its products. The buyout is a big payday for the founders Ruth Mathews and James Burnie, who still own a 7% stake. During the takeover negotiations the founders secured NeuTecs operations at the current facility in Manchester for at least two years. The sale of the company came just three weeks after AstraZeneca agreed to buy Cambridge Antibody for Euro1.1 billion. Besides the Neutec deal the antibiotics market has seen amany known players disappear. One of the most prominent was the US-based Vicuron, bought by Pfizer for $1.9 billion. New companies have nevertheless emerged as Roche (Basilea), Sanofi-Aventis (Novexel), Sandoz (Nabriva) and Bayer (Aicuris) span out their infectious disease businesses.

BioPeople

11.06.2011

Dutch biotech firm Mucosis B.V. (Groningen) has appointed Thomas Johnston as its Chief Business Officer. Johnston, who comes in from Novavax Inc, will have global responsibility for the licensing and marketing of the company’s...

Clinical Trial

10.06.2011

London – In mid-May, the EMA adopted two guidelines concerning the centralised market authorisation that is relevant for all biologics. One is on pre-submission procedural advice, the other on post-authorisation procedural...

Politics / Law

10.06.2011

London – In mid-May, the European Medicines Agency was under pressure from the European Parliament, which postponed signing off on its accounts for the financial year 2009. The decision came on the heels of a critical report from...

Politics / Law

10.06.2011

Parma – The EU’s food watchdog EFSA published two biotech-relevant guidelines in May – one on gut and immune system related health claims, and one on GMO food and feed safety assessments.The update on risk assessments of food and...

Tech Review

10.06.2011

Increasing evidence suggests that the cellular response to ligand-induced receptor activation is influenced by receptor expression levels and downstream signaling components that can be different amongst various cell types. There...

Clinical Trial

10.06.2011

Bethesda – VEGF-A blockers Lucentis and Avastin have shown similar efficacy in patients with age-related macular degeneration (AMD), according to one-year results from the CATT study performed on more than 1,000 AMD patients....

BioPeople

09.06.2011

Ireland’s ICON plc (Dublin) has named Elizabeth Thomas as Vice President and General Manager of the company’s Bioanalytical Operations in Manchester (UK). Thomas, who comes in from AstraZeneca, brings ICON over 30 years’...

Clinical Trial

05.06.2011

Swedish Medivir AB (Huddinge) and Belgian Tibotec BVBA (Beerse) have reported positive data from an ongoing Phase IIb study (48 weeks) with Tibotec’s hepatitis C virus protease blocker TMC435 in patients that responded poorly to...

Clinical Trial

01.06.2011

Hamburg/Ingelheim: Evotec AG’s second oral compound against neuropathic pain has reached clinical development stage. The progress triggered a EUR 2 million milestone from Boehringer Ingelheim that will pay all clinical...

BioPeople

01.06.2011

Vienna-based Intercell AG replaced former CEO Gerd Zettlmeissl with the company’s former COO Thomas Lingelbach in May. Lingelbach, who joined Intercell in 2006 after executive positions at the German branches of both Chiron and...

Displaying results 151 to 160 out of 1983

< Previous 151-160 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive/browse/15/article/100-premium-novartis-buys-antibiotics-specialists-neutec-pharma.html

Events

All Events

Stock list

All quotes

TOP

  • THROMBOGENICS (B)9.69 EUR9.24%
  • NOVACYT (F)4.80 EUR9.09%
  • HYBRIGENICS (F)1.85 EUR7.56%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • THERAMETRICS (CH)0.08 CHF-11.11%

TOP

  • WILEX (D)3.15 EUR303.8%
  • SANTHERA (CH)68.90 CHF102.6%
  • ADDEX (CH)4.06 CHF82.1%

FLOP

  • MERCK KGAA (D)64.28 EUR-49.5%
  • HYBRIGENICS (F)1.85 EUR-29.4%
  • PROSENSA (NL)9.24 USD-24.4%

TOP

  • SANTHERA (CH)68.90 CHF3433.3%
  • GW PHARMACEUTICALS (UK)422.75 GBP769.5%
  • PAION (D)2.80 EUR311.8%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-92.1%
  • THROMBOGENICS (B)9.69 EUR-69.2%

No liability assumed, Date: 23.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...


Current issue

All issues

Product of the week

Products